Bruno, Laura A., Pueblas Castro, Celeste, Demaría, Agostina, Prado, Lineia, Fascetto Cassero, Clara G., Saposnik, Lucas M., Páez Córdoba, Federico, Rodriguez, Juan Manuel, Piccini, Giulia, Antonelli, Roberta, and others. (2025) Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity. npj Vaccines, 10 (1). Article Number 108. ISSN 2059-0105. (doi:10.1038/s41541-025-01156-3) (KAR id:110135)
|
PDF
Publisher pdf
Language: English 
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
|
|
|
Download this file (PDF/3MB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.1038/s41541-025-01156-3 |
|
Abstract
COVID-19 vaccine adaptation is critical to respond to continuously emerging SARS-CoV-2 variants with enhanced immune evasion. The ARVAC protein subunit vaccine, based on the receptor binding domain of the spike protein of SARS-CoV-2, has been adapted to XBB.1.5 and JN.1 variants, as monovalent and bivalent formulations. Preclinical studies in mice showed that ARVAC XBB.1.5 and JN.1 monovalent vaccines induced strong neutralizing antibodies against XBB and JN.1 lineages, though with limited efficacy against phylogenetically distant variants. By contrast, bivalent formulations combining Gamma antigen with either XBB.1.5 or JN.1 antigens demonstrated superior cross-neutralizing activity, covering variants from Ancestral to JN.1. Additionally, Gamma-containing bivalent vaccines elicited neutralizing antibodies against SARS-CoV-1, highlighting their potential for broad-spectrum immunity. Cellular immune studies confirmed robust CD4+ T cell activation across all formulations. These findings support the continued adaptation of ARVAC to current circulant variants and propose ARVAC bivalent vaccines containing the Gamma antigen as a strategy for induction of pan-sarbecovirus immunity.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1038/s41541-025-01156-3 |
| Subjects: | Q Science > QR Microbiology > QR355 Virology |
| Institutional Unit: | Schools > Medway School of Pharmacy |
| Former Institutional Unit: |
There are no former institutional units.
|
| Funders: | Wellcome Trust (https://ror.org/029chgv08) |
| Depositing User: | Nigel Temperton |
| Date Deposited: | 30 May 2025 20:21 UTC |
| Last Modified: | 22 Jul 2025 09:23 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/110135 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Temperton, Nigel J..
| Creator's ORCID: |
 https://orcid.org/0000-0002-7978-3815
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
